Market Place
Sourcing Support
Entero and ADC-like biotech Journey pen reverse merger
14 Nov 2024 //
FIERCE BIOTECH
Journey Medical Reports Q3 2024 Financial Results & Corporate
12 Nov 2024 //
GLOBENEWSWIRE
FDA approves Journey Medical`s drug for long-term skin condition
05 Nov 2024 //
REUTERS
Journey Medical Presents DFD-29 Data at Dermatology Conference
25 Oct 2024 //
GLOBENEWSWIRE
Journey Medical To Join 3rd Annual Roth Healthcare Conference
03 Oct 2024 //
GLOBENEWSWIRE
Journey Medical To Participate In Lake Street Conference
09 Sep 2024 //
GLOBENEWSWIRE
Journey Medical To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Journey Medical Reports Q2 2024 Results And Corporate Highlights
12 Aug 2024 //
GLOBENEWSWIRE
Journey Medical To Announce Q2 2024 Results On August 12
06 Aug 2024 //
GLOBENEWSWIRE
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
11 Jul 2024 //
GLOBENEWSWIRE
Journey Medical To Participate In A.G.P. Virtual Showcase
15 May 2024 //
GLOBENEWSWIRE
Journey Medical Q1 2024 Financials, Corporate Highlights
13 May 2024 //
GLOBENEWSWIRE
Journey Medical To Announce Q1 2024 Financial Results On May 13
07 May 2024 //
GLOBENEWSWIRE
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
01 May 2024 //
GLOBENEWSWIRE
Journey Medical at Planet MicroCap Showcase: Vegas 2024
25 Apr 2024 //
GLOBENEWSWIRE
Journey Medical Corporation Reports Full-Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Journey Medical U.S. FDA Acceptance of New Drug Application for DFD-29
18 Mar 2024 //
GLOBENEWSWIRE
Journey Medical Announces U.S. FDA Acceptance of NDA for DFD-29
18 Mar 2024 //
GLOBENEWSWIRE
Journey Medical to Announce Year End 2023 Financial Results on March 21, 2024
15 Mar 2024 //
GLOBENEWSWIRE
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
13 Mar 2024 //
GLOBENEWSWIRE
Journey Medical Announces Presentation from Phase 1 Assessing Impact of DFD-29
11 Mar 2024 //
GLOBENEWSWIRE
Journey Medical Corporation Submits NDA to FDA for DFD-29 to Treat Rosacea
05 Jan 2024 //
GLOBENEWSWIRE
Journey Medical Secures Credit Facility with SWK Holdings for up to $20 Million
02 Jan 2024 //
GLOBENEWSWIRE
Journey Medical Announces Completion of Meeting with the FDA for DFD-29
06 Dec 2023 //
GLOBENEWSWIRE
Journey Medical Corporation Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29
20 Oct 2023 //
GLOBENEWSWIRE
Journey Medical Enters into an Exclusive License Agreement with Maruho
06 Sep 2023 //
GLOBENEWSWIRE
Journey Medical Corporation Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Journey Medical to Announce Q2 2023 Financial Results on August 8, 2023
02 Aug 2023 //
GLOBENEWSWIRE
Journey Medical to Announce Second Quarter 2023 Financial Results
19 Jul 2023 //
GLOBENEWSWIRE
Journey Medical Announces Results from Two Phase 3 Trials Evaluating DFD-29
11 Jul 2023 //
GLOBENEWSWIRE
Journey Medical Expects Results from the Phase 3 Trials Evaluating DFD-29
03 Jul 2023 //
GLOBENEWSWIRE
Journey Medical Announces Positive Data from PI Trial Assessing Impact of DFD-29
13 Jun 2023 //
GLOBENEWSWIRE
Journey Medical Corporation Reports First Quarter 2023 Financial Results
22 May 2023 //
GLOBENEWSWIRE
Journey Medical to Announce First Quarter 2023 Financial Results on May 22, 2023
19 May 2023 //
GLOBENEWSWIRE
Journey Medical Announces Postponement of First Quarter Financial Results
11 May 2023 //
GLOBENEWSWIRE
Journey Medical Corporation to Announce 1Q 2023 FYR on May 11, 2023
04 May 2023 //
GLOBENEWSWIRE
Journey Medical Reports Full-Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
Journey Medical Corporation to Announce Year End 2022 Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
Journey Medical Announces Completion of Treatment Assessing Impact of DFD-29
16 Mar 2023 //
GLOBENEWSWIRE
Journey Medical Corporation to Participate in the 35th Annual ROTH Conference
07 Mar 2023 //
GLOBENEWSWIRE
Journey Medical Corporation Appoints Joseph Benesch as Interim CFO
20 Jan 2023 //
GLOBENEWSWIRE
Journey Medical completes subject enrolment in PPR therapy trial
11 Jan 2023 //
CLINICALTRIALSARENA
Journey Medical Completes Enrollment in PIII Clinical Trials Evaluating DFD-29
10 Jan 2023 //
GLOBENEWSWIRE
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic
20 Dec 2022 //
GLOBENEWSWIRE
Journey Medical Corporation to Participate in Cantor Medical & Dermatology
05 Dec 2022 //
GLOBENEWSWIRE
Journey Medical Corporation Reports3Q 2022 Financial Results & Recent Highlights
10 Nov 2022 //
GLOBENEWSWIRE
Journey Medical Announces Settlement Agreements Pertaining to Patent Exclusivity
24 May 2022 //
GLOBENEWSWIRE
Journey Medical Corp to Present at B. Riley Securities 22nd Annual Conference
23 May 2022 //
GLOBENEWSWIRE
Journey Medical Corp to Announce First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Journey Medical Corp to Present at Virtual Fortress Biotech R&D Summit
04 Apr 2022 //
GLOBENEWSWIRE
Journey Medical Corporation Reports Full-Year 2021 Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
Journey Medical Corp to Release Year End 2021 Financial Results
18 Mar 2022 //
GLOBENEWSWIRE
Journey Medical Corp says First Patient Dosed in PIII Trial Evaluating DFD-29
17 Mar 2022 //
GLOBENEWSWIRE
Freeline Begins Dosing in the P 1/2 B-LIEVE Dose-Confirmation Trial
09 Mar 2022 //
GLOBENEWSWIRE
Journey Medical Corp to Present at the 34th Annual ROTH Conference
09 Mar 2022 //
GLOBENEWSWIRE
Journey Medical Acquires 2 FDA-Approved Topical Minocycline Products from VYNE
13 Jan 2022 //
GLOBENEWSWIRE
JMC Enters into Agreement with Dr. Reddy’s to Develop & Commercialize DFD-29
30 Jun 2021 //
GLOBENEWSWIRE
